HormoneFDA Approved

Lonapegsomatropin (Skytrofa)

Subcutaneous injection

Overview

Lonapegsomatropin is a long-acting prodrug of somatropin created through site-specific PEGylation that releases active growth hormone after administration. The PEG moiety extends circulating half-life and enables once-weekly dosing for pediatric growth hormone deficiency.

Mechanism of Action

This represents a transient modification strategy in which the PEG is cleaved to yield native growth hormone..

Research Summary & Key Findings

The Phase 3 enliGHten trial published in Lancet Child & Adolescent Health in 2021 demonstrated non-inferiority to daily somatropin in improving annualized height velocity in children with growth hormone deficiency. FDA approval was granted in August 2021 for pediatric patients aged one year and older. Safety and efficacy profiles were comparable to conventional daily somatropin formulations.

Clinical Status

FDA Approved

Lonapegsomatropin (Skytrofa) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection

Related Peptides in Hormone

Find a Provider

Find a verified provider who offers Lonapegsomatropin (Skytrofa) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Lonapegsomatropin (Skytrofa).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.